Feature | Sudden Cardiac Arrest | October 07, 2019

Sudden Cardiac Arrest Patient Walks to Ambulance Thanks to Wearable Defibrillator

LifeVest shocks Cleveland man and saves his life at home, prescribed wearable defibrillator just three days earlier

The life of Afib patient Glynn Crawford was saved three days after being prescribed a Zoll LifeVest wearable defibrillator by his cardiologist Barbara Williams, M.D., at   University Hospitals Ahuja Medical CenterShe identified him as a high-risk for sudden cardiac arrest.

The life of Afib patient Glynn Crawford was saved three days after being prescribed a Zoll LifeVest wearable defibrillator by his cardiologist Barbara Williams, M.D., at   University Hospitals Ahuja Medical CenterShe identified him as a high-risk for sudden cardiac arrest.

October 7, 2019 — Glynn Crawford was hospitalized at University Hospitals Ahuja Medical Center in late June/early July for chronic abdominal issues associated with his irregular heartbeat (paroxysmal atrial fibrillation) and weakened heart muscle (non-ischemic cardiomyopathy). After prescribing medications, UH Harrington Heart and Vascular Institute cardiologist Barbara Williams, M.D., determined Crawford had increased risk of sudden cardiac arrest (SCA). She recommended a Zoll LifeVest wearable defibrillator, which is designed to continuously monitor the wearer’s heart, detect life-threatening rapid heart rhythms and automatically deliver a treatment shock to restore a normal rhythm. The device also alerts bystanders when a shock has been delivered so they can contact emergency medical personnel.

Just three days after leaving the hospital, the LifeVest saved the 68-year-old’s life when he was lying in bed at home in Warrensville Heights, Ohio. “The next thing I knew, I woke up with my wife telling me that the vest had shocked my heart back into rhythm,” said Crawford. “The alarm had alerted her to what was happening and she called 911. When they arrived, I was able to walk outside to the ambulance myself.”

The following day, a permanent defibrillator was implanted in his chest. 

“Very grateful, I can’t even begin to explain it,” said Crawford. “I wouldn’t be alive without it, because I didn’t realize that I was as sick as I was at the time.”

The life of Afib patient Glynn Crawford was saved three days after being prescribed a Zoll LifeVest wearable defibrillator by his cardiologist Barbara Williams, M.D., at   University Hospitals Ahuja Medical CenterShe identified him as a high-risk for sudden cardiac arrest.

The Zoll Lifevest is worn under the patient's clothes as a precaution against sudden cardiac arrest (SCA).

SCA occurs when a failure of the heart’s electrical system triggers a dangerously fast heartbeat - so fast that it causes the heart to quiver or shake instead of pumping blood to the body and brain. Patients have an increased risk of SCA following a cardiac event, such as a heart attack or new diagnosis of heart failure.

“Glynn is the perfect example of a good candidate for LifeVest,” said Mauricio Arruda, M.D., director, clinical electrophysiology and pacing at UH Cleveland Medical Center. “Another potential benefit of LifeVest would be to someone after a heart attack resulting in decreased heart function who undergoes intervention to re-open a blocked coronary artery. Such a patient may be at risk of sudden death for a period of time.”

Arruda says it is important for heart patients to have awareness about devices like LifeVest. “These devices are potentially under-prescribed and underutilized, particularly at centers with limited education on this issue or few heart rhythm specialists,” he explained.

Today, Crawford’s abdominal issues have resolved and his medications are working well to manage his cardiovascular conditions.

October is SCA Awareness Month. According to the Sudden Cardiac Arrest Foundation, nearly 350,000 people experience out-of-hospital cardiac arrest every year and in more than half of those instances there is no witness.

 

Related SCA Content:

Wearable Defibrillator Offers a Bridge Therapy

VIDEO: Should Student Athletes be Screened for Sudden Cardiac Arrest? — Interview With Malissa Wood, M.D.

Survey Shows Majority of Americans Unaware of Effective Treatment Options to Protect Against Sudden Cardiac Arrest

 

Related Content

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Dr. Markus Krane, deputy director of the Cardiac and Vascular Surgery Unit at the DHM helped compile an atlas of the heart and discovered myosin binding protein H-like (MYBPHL) occurs only in the atria of the heart. Researchers began using it as a blood test biomarker to assess the success of atrial fibrillation ablation procedures.

Feature | Atrial Fibrillation | July 24, 2019
July 24, 2019 — Atrial fibrillation (AFib) is a common abnormal heart rhythm.
New Technology Improves Atrial Fibrillation Detection After Stroke
News | Atrial Fibrillation | July 19, 2019
A new method of evaluating irregular heartbeats outperformed the approach that’s currently used widely in stroke units...
An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures.

An screen shot of the Abbott Focal Impulse and Rotor Modulated (FIRM)-guided ablation system used to guide AF ablation procedures. 

News | Atrial Fibrillation | May 14, 2019 | Dave Fornell, Editor
May 14, 2019 – The first prospective, multicenter, randomized, controlled trial to compare conventional pulmonary vei
The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial.

The Parasym Salustim device ear clip stimulates the vagus nerve, which was found to reduced AF burden compared with a sham procedure in the TREAT AF trial. 

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A randomized clinical trial effectively used nerve stimulation through an ear clip to reduce...
More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

More than 60,000 from the general population in Belgium were screened for AFib using only a smartphone app in the DIGITAL-AF II study. The study used the FibriCheck app found 791 participants has measurements indicative for AF.

News | Atrial Fibrillation | May 13, 2019
May 13, 2019 — A digital screening for...
Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

Rivaroxaban is among four new oral anticoagulants (NOAC) now recommended by atrial fibrillation guidelines over the old standard of warfarin.

 

Feature | Atrial Fibrillation | January 30, 2019
January 30, 2019 — Updated atrial fibrillation (AFib) treatment guidelines released this week now recommend new oral
Aurigen Medical Atrial Fibrillation Device Wins ICI Innovation Award
News | Atrial Fibrillation | December 18, 2018
Irish medical device company AuriGen Medical won the prestigious Global Innovation Award at the International...
Overlay Init